{"DataElement":{"publicId":"4449913","version":"1","preferredName":"Patient Contraception Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to patient's criteria to determine eligibility based on the use of prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"CONT_EL_DT_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3151263","version":"1","preferredName":"Patient Contraception Eligibility Determination","preferredDefinition":"information related to patient's criteria to determine eligibility based on the use of prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"2233604v1.0:3151261v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3151261","version":"1","preferredName":"Contraception Eligibility Determination","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C37932:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92982EC3-9A58-A7AE-E040-BB89AD434360","latestVersionIndicator":"Yes","beginDate":"2010-10-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-14","modifiedBy":"ONEDATA","dateModified":"2010-10-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92982EC3-9A69-A7AE-E040-BB89AD434360","latestVersionIndicator":"Yes","beginDate":"2010-10-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876423","version":"1","longName":"Consents & Contraceptive Guidelines","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PT_CONTR_ELG_CD_IND","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Does patient, women of childb","type":"Preferred Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex -3","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and for duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and up to 90 days following completion of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is male and sexually active, patient agrees to use adequate contraception prior to study entry, for the duration of study participation and for 31 weeks after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation and for 31 weeks after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of MLN8237 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient is male and is sexually active with a women of child bearing potential, patient agree to use adequate contraception prior to study entry, for the duration of study participation and for 31 weeks after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does female patient of childbearing potential, agree to use an adequate method of contraception throughout the study and for up to 12 weeks after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Does patient, woman of childbearing potential and men, agree to use two forms of contraception, prior to study entry, for duration of study participation and for 31 weeks after the last dose nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use two highly effective forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 3 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after the last CDX-011 (glembatumumab vedotin) dose?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after the last dose of MLN0128 and AZD9291?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men with female partner of childbearing potential, agree to use adequate contraception prior to study entry, during study participation and for 4 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men with partners of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 2 months after completion of study?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after the last dose AZD1775 and belinostat administration?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception, as listed in protocol, prior to study entry, for the duration of study participation, and for 3 months for women and 6 months for men following the date of the last dose of AZD9291 and/or necitumumab?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months for women and 6 months for men following the date of the last dose of AZD9291 and/or navitoclax?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and for 4 months after completion of study drugs?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal contraception not allowed) prior to study entry, for duration of study participation and for 4 months after completion of study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after stopping nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of AT13387 (onalespib) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception during treatment with MM-938 for 90 days following the final dose of Veliparib and MM-398?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and for 4 months after completion of IPdR administration?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [eg. USPI, SmPC, etc]) after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and up to 90 days following completion of ibrutinib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception during treatment with MM-398 and for 90 days following the final dose of Veliparib and MM-398?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [eg, USPI, SmPC, etc;]) after the last dose of study drug, or agree to completely abstain from heterosexual intercourse?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 5 months (150 days) after the last dose of study agent (men must also agree to use adequate contraception for at least 5 months (150 days) after completion of atezolizumab and/or ABT-888 administration)?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use two highly effective forms of contraception for the duration of study participation and for 6 weeks after completion of olaparib and cediranib administration (12 weeks for men)?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception, prior to study entry, for duration of study participation and for 5 months after completion of study drug administration (completion of atezolizumab administration)?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and for 3 months after completion of study drugs (4 months for men)?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after dosing with selumetinib ceases?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception during study participation, and for 6 months after completion of bevacizumab therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after dosing with AZD6244 ceases?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months following participation?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for 150 days after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 150 days after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Does female patient childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 5 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Does female patient childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 7 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 5 months(150 days) after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after dosing with AZD6244 ceases?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception, prior to study entry, for duration of study participation and for 5 months (150 days) after completion of study drug administration (completion of atezolizumab administration)?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 120 days after last dose of study therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of olaparib and ramucirumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 180 days after the last dose of paclitaxel?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months for women and 7 months for men after last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men with partners of childbearing potential, agree to use adequate contraception (barrier method of birth control, or abstinence; hormonal contraception is not allowed due to drug-drug interactions which can render hormonal contraceptives ineffective) prior to study entry, for duration of study participation and for 4 months after completion of study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 3 months after completion of Olaparib and Ramucirumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men who are sexual partner of a female of childbearing portenial, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Does female patient of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 7 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men who are sexual partner of a female of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for duration of study participation and for 4 months after completion of IPdR administration?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and up to 3 months after end of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men with partners of childbearing potential, agree to use adequate contraception (hormonal contraception not allowed) prior to study entry, for duration of study participation and for 4 months after completion of study drug administration?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Does patient, women of child bearing potential and men, agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence; sterilization) prior to the study, for the duration of study participation, and for 3 months after completion of administration of Aza-TdC?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"If patient is female of childbearing potential uses hormonal contraceptive, does patient agree to use an additional barrier method of contraception while on study treatment and for 30 days after discontinuation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men and their partners who are sexually active, agree to use two highly effective forms of contraception in combination (see olaparib 1B page 161-162 for acceptable methods) for the duration of study participation and for 3 months after completion of olaparib and cediranib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and for the duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during study participation, and for 5 months (150 days) after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Does patient, men and women of childbearing potential agree to use adequate contraception prior to study entry, for the duration of study participation, and for 4 months after completion of administration of either agent?","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for duration of study participation and for 6 months after completion of MK-3475 (Pembrolizumab) in combination with KW-0761 (Mogamulizumab ) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use highly effective contraception prior to study entry, for the duration of study participation, and for at least 5 months (150 days) after the last dose of study agent; men must also agree to use two highly effective forms of contraception in combination for at least 5 months (150 days) after completion of atezolizumab and/or olaparib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"If patient is male and is sexually active with a woman of child bearing potential, patient agrees to use adequate contraception prior to study entry, for the duration of study participation and for 7 months after the last dose of investigational product?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after last dose of copanlisib?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and during study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 83","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use two forms of contraception prior to study entry and for duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use contraception prior to study entry and for duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 5 months(150 days) after the last dose of study agent?","url":null,"context":"Theradex"},{"name":"Theradex - 84","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after the last dose study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 86","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men and their partners who are sexually active, agree to use two highly effective forms of contraception in combination (see olaparib and cedirabnib IB  for acceptable methods) for the duration of study participation and for 6 months after last dose of olaparib and at least 6 weeks after last dose of cediranib and least 90 days after the last dose of Durvalumab monotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 85","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men able to father children who have female partners of child-bearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after trial participant's final dose of M6620 or irinotecan (whichever agent is completed last)?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use highly effective contraception (as per section 3.3.10) prior to study entry, for the duration of study participation, and for 3 months after completion of study?","url":null,"context":"Theradex"},{"name":"Theradex - 87","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 88","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 31 weeks after the last dose of nivolumab or ipilimumab AND if patient is male, and is the sexual partner of a female of child-bearing potential, does patient agree to use a contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of nivolumab or ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 89","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use 1 highly effective method and 1 additional (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of MLN4924 (pevonedistat) and belinostat of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 90","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 6 months after last dose of a study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 91","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use 1 highly effective method and 1 additional (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 92","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 3 months after completion of the administration of study agents?","url":null,"context":"Theradex"},{"name":"Theradex - 95","type":"Alternate Question Text","description":"Does patient planning to conceive or father children agree to use adequate contraception prior to study entry, during study participation and for 120 days after the last dose of study agent(s)?","url":null,"context":"Theradex"},{"name":"Theradex - 96","type":"Alternate Question Text","description":"If sexually active and of childbearing potential, does patient and their partners agree to use two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after the last dose of study drug(s)?","url":null,"context":"Theradex"},{"name":"Theradex - 93","type":"Alternate Question Text","description":"If sexually active and of childbearing potential, does patient and their partners agree to use two highly effective forms of contraception in combination throughout the period of taking study treatment and for 6 months after the last dose of study drug(s)?","url":null,"context":"Theradex"},{"name":"Theradex - 99","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after completion of M3814 and avelumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 98","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after last dose of copanlisib?","url":null,"context":"Theradex"},{"name":"Theradex - 101","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of M3814 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 100","type":"Alternate Question Text","description":"Does patient and partners, agree to use two highly effective forms of  contraception prior to study entry, during study participation, and for 7 months after last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 102","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for 7 months after completion of GSK525762C administration?","url":null,"context":"Theradex"},{"name":"Theradex - 103","type":"Alternate Question Text","description":"If sexually active, does patient women of childbearing potential and men with partners of childbearing potential agree to use dual contraception for the duration of study participation and for 7 months for women and 5 months for men after last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 106","type":"Alternate Question Text","description":"Does patient,  women of childbearing potential and their partners, who are sexually active, agree to use  TWO highly effective forms of contraception in combination from the signing of the informed consent, during period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse?","url":null,"context":"Theradex"},{"name":"Theradex - 108","type":"Alternate Question Text","description":"Does female of childbearing potential and man, agree to use adequate contraception for the duration of the study and for at least 28 days after discontinuation from study?","url":null,"context":"Theradex"},{"name":"Theradex - 105","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after completing treatment administration?","url":null,"context":"Theradex"},{"name":"Theradex - 112","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for duration of study participation and for 4 months afterwards?","url":null,"context":"Theradex"},{"name":"Theradex - 104","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months for women and 7 months for men after the completion of all study treatments?","url":null,"context":"Theradex"},{"name":"Theradex - 110","type":"Alternate Question Text","description":"If patient is a female of childbearing potential, does patient agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer as mandated by local labeling [e.g. USPI, SmPC, etc.]) after the last dose of study drug or practice true abstinence when this is in line with the preferred and usual lifestyle of the patient?","url":null,"context":"Theradex"},{"name":"Theradex - 113","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception during study participation, and for 12 weeks after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 114","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 weeks for women and 3 months for men after completion of KRT-232 (AMG 232) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 116","type":"Alternate Question Text","description":"Does women of childbearing potential and male partners, agree to use a double-barrier method of birth control or practice continuous abstinence from heterosexual contact throughout the study and for seven months after the end of the last treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 115","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, for the duration of study participation, and for 1 month after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 117","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of peposertib M3814 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 97","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after completion of berzosertib?","url":null,"context":"Theradex"},{"name":"Theradex - 122","type":"Alternate Question Text","description":"Does patient, women of childbearing potential agree to use a highly effective method of contraception for the duration of study participation, and for at least 7 months after completing study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 119","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 5 months after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 125","type":"Alternate Question Text","description":"If patient is a woman of child-bearing potential and men, must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of investigational treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 120","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after completion of BAY 1895344 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 121","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and continue for 4 months after the last dose of both Hu5F9-G4 (magrolimab) and mogamulizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 111","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation and for at least 7 months for women and 4 months for men after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 123","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception for the duration of study participation, and for 6 months after completion of BAY 1895344 therapy or 4 months after completion of pembrolizumab therapy, whichever is later?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of the study and at least 6 months after receiving the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 126","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during study participation, and for 5 months after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 127","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 4 months after completion of rogaratinib (BAY 1163877)?","url":null,"context":"Theradex"},{"name":"Theradex - 118","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after completion of BAY 1895344 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 128","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and males of reproductive potential who are sexually active, agrees to use adequate contraception prior to study entry, for the duration of study participation, and 4 months after completion of chemotherapy preparative administration or until CAR is no longer detectable, whichever is later?","url":null,"context":"Theradex"},{"name":"Theradex - 109","type":"Alternate Question Text","description":"Is patient, women of childbearing potential and men with female partners of childbearing potential, willing to use an adequate method of contraception prior to first dose of study therapy and for the course of the study through 120 days after the last dose of study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 94","type":"Alternate Question Text","description":"Does patient, women of childbearing/reproductive potential and men of reproductive potential, agree to use adequate contraception prior to study entry, during study participation, and for 6 months for women and 3 months for men after the last dose of study therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 134","type":"Alternate Question Text","description":"Does patient agree to use reliable contraception (hormonal or barrier method of birth control; abstinence) throughout the study and for 7 months after study treatment discontinuation for women, and for 4 months for men?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 5 months (150 days) after the last dose of  atezolizumab or 6 months (180 days) after the last dose of bevacizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 133","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 5 months after the last dose of investigational drug for women and 7 months after the last dose of investigational product for men?","url":null,"context":"Theradex"},{"name":"Theradex - 131","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men, agree to use a highly effective method of contraception prior to study entry, for the duration of study participation and for women an additional 3 weeks after completion of abemaciclib?","url":null,"context":"Theradex"},{"name":"Theradex - 107","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men with female partners of childbearing potential, agree to use adequate contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 135","type":"Alternate Question Text","description":"Does patient women of child-bearing potential, agree to continued abstinence from receptive vaginal intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide?","url":null,"context":"Theradex"},{"name":"Theradex - 130","type":"Alternate Question Text","description":"If the patient is a woman of child-bearing potential does the patient agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 7 months after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 132","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for at least 7 months (WOCBP only) after the last dose of study drug and 6 months after completion of study drug administration for men?","url":null,"context":"Theradex"},{"name":"Theradex - 124","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than 1% per year (bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives [with additional barrier method of birth control while on study treatment and for 6 months after discontinuation of tazemetostat or the combination of tazemetostat, dabrafenib and trametinib] that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the treatment period, for 6 months after tazemetostat discontinuation, or for 6 months after discontinuation of the combination of tazemetostat, dabrafenib and trametinib?","url":null,"context":"Theradex"},{"name":"Theradex -137","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential (WOCBP) and men, agree to use adequate contraception prior to study entry and for the duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 136","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 90 days after the last dose of study treatment or completion of NT-17 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 138","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation?","url":null,"context":"Theradex"},{"name":"Theradex - 137","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after completion of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 140","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of study therapy?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Is patient a sexually active participant of reproductive potential who agrees to use an effective contraceptive method for the duration of study participation?","url":null,"context":"COG"},{"name":"Theradex - 139","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and for 6 months after completion of study therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use two effective methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of Telaglenastat (CB-839) HCl, carfilzomib, and dexamethasone administration?","url":null,"context":"Theradex"},{"name":"Theradex - 141","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal birth control or abstinence) prior to study entry, during study participation, and for 6 months after completion of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 142","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 4 months after the completion of ZEN003694 (ZEN-3694) and binimetinib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 143","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation and for at least 7 months after dosing with study drugs ceases?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after completion of M6620 (VX-970, berzosertib) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 144","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study treatment, and for 6 months after the last dose of drug?","url":null,"context":"Theradex"},{"name":"Theradex - 146","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of durvalumab monotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 147","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text 1","type":"Alternate Question Text","description":"If the participant is sexually active, do they agree to use a medically effective contraceptive method during treatment on study to prevent pregnancy?","url":null,"context":"NRG"},{"name":"Theradex - 145","type":"Alternate Question Text","description":"Does patient, female patients of child-bearing potential and male patients, agree to use adequate contraception prior to study entry, for the duration of study participation, for 90 days after the last dose of selinexor, and for 150 days after the last dose of atezolizumab, whichever is longer?","url":null,"context":"Theradex"},{"name":"Theradex - 148","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men agree to use adequate contraception prior to the study, for the duration of study participation, and 3 weeks after completion of ZEN003694 and abemaciclib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 149","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 5 months after the last dose of Atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 150","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 7 months after. combination ZEN003694 (ZEN-3694) and talazoparib?","url":null,"context":"Theradex"},{"name":"Theradex -153","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after the last dose study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 151","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 180 days after the last dose of temozolomide?","url":null,"context":"Theradex"},{"name":"Theradex - 152","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, 1 month after completion of erdafitinib single agent, and 5 months after erdafitinib and atezolizumab combination?","url":null,"context":"Theradex"},{"name":"Theradex - 153","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry and for the duration of study participation and 4 months after completion of novobiocin administration?","url":null,"context":"Theradex"},{"name":"Theradex - 154","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and 90 days after completion of CA-4948, nab-paclitaxel, and gemcitabine administration?","url":null,"context":"Theradex"},{"name":"Theradex - 155","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and 180 days after the last dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 156","type":"Alternate Question Text","description":"Does patient, woman of childbearing potential and men, agree to use reliable contraception (double-barrier method) throughout the study and for 7 months after the last treatment with Lutetium Lu 177 Dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 157","type":"Alternate Question Text","description":"Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, during study participation and 6 months after completion of M1774 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 158","type":"Alternate Question Text","description":"If patient is a woman of childbearing potential, is she willing to use an adequate method of contraception for the course of the study through 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin?","url":null,"context":"Theradex"},{"name":"Theradex - 159","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for at least 4 months after completion of CBX-12 administration?","url":null,"context":"Theradex"},{"name":"Theradex - 160","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and during study participation, and for 2 weeks after completion of APG-1252  and cobimetinib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 161","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential, and men who are sexually active and their partner who may become pregnant, agree to use contraception during treatment and at least for 6 months (women) and 4 months (men) after the last dose of magrolimab and olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 162","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration?","url":null,"context":"Theradex"},{"name":"Theradex - 163","type":"Alternate Question Text","description":"If patient has a female partner of child-bearing potential, does she agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of M1774 administration by patient?","url":null,"context":"Theradex"},{"name":"Theradex - 164","type":"Alternate Question Text","description":"If patient is WOCBP (defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal), has patient agreed to use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug?","url":null,"context":"Theradex"},{"name":"Theradex - 165","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and male partner, agree to use a double-barrier method of birth control or practice continuous abstinence from heterosexual contact throughout the study and for seven months after the date of their last treatment with Lutetium Lu 177 Dotatate for women, and four months for men?","url":null,"context":"Theradex"},{"name":"Theradex - 166","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and one month after completion of erdafitinib administration?","url":null,"context":"Theradex"},{"name":"Theradex - 167","type":"Alternate Question Text","description":"Does patient, women of childbearing potential and men, agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of mosunetuzumab administration and 12 months after completion of rituximab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 168","type":"Alternate Question Text","description":"Does patient women of child-bearing potential and men agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 5 months after the last dose of nivolumab and duvelisib for women and 7 months after the last dose of investigational product for men?","url":null,"context":"Theradex"},{"name":"Theradex - 169","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after durvalumab administration?","url":null,"context":"Theradex"},{"name":"Theradex - 170","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men with partners of women of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after the last dose of selinexor and 7 months for female and 4 months for male patients after the last dose of bortezomib?","url":null,"context":"Theradex"},{"name":"Theradex - 171","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men with partners of women of childbearing potential, agree to use adequate contraception prior to study, for the duration of study participation, and 4 months after completion of study treatment administration?","url":null,"context":"Theradex"},{"name":"Theradex - 172","type":"Alternate Question Text","description":"Does patient, women of child-bearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months following the last dose of study drug?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-438A-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeDescription":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2023.8.8 AQT added per ticket request CADSR0002710. ak","unresolvedIssues":null,"deletedIndicator":"No"}}